New Cancer Drug Zaltrap Discounted by 50%

By Curt Pesman and Mary Miller In an unusual move, sanofi pharmaceutical company has instituted a 50 percent discount, effective immediately, on its latest cancer drug Zaltrap.  The reason for the sharp price drop, company officials said, was “market resistance” to the initial price. Zaltrap was approved in August by the FDA for second-line treatment for metastatic…  Read More

Cancer Costs Grow, But Stay in Line with Other Medical Expense

Over the past twenty years, the cost of caring for cancer patients doubled, but still remained about 5 percent of all medical expense in the United States. An increase in the number of people with cancer — fueled by an aging population — drove the growing expense rather than a greater cost per individual. Expressed in…  Read More